research chemical raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-03-16 and is reviewed periodically as new material appears.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
== History of DHIS development == The original District Health Information Software (DHIS) was developed for three health districts in Cape Town as part of the Health Information Systems Programme (HISP), a collaborative research project between the University of Oslo and the University of the Western Cape that began in 1994.
== Shelf-life and safety == The purpose of IMF foods is to achieve a water activity that the food can be stored safely without refrigeration. However, the food is not sterile. Staphylococcus aureus is a microorganism of concern as it can grow and produce specific enterotoxins in water activities of 0.83-0.86 under aerobic conditions. Because of this, proper handling, storage, hygiene and good manufacturing practices are necessary to prevent Staphylococcus aureus. Molds of Aspergillis and Penicillium species can grow and produce harmful mycotoxins at water activity 0.77-0.85. Salmonella and Bacillus cereus are the primary pathogens of concern with low-moisture foods and IMFs. Most illnesses associated with low-moisture foods or IMFs have been caused by Salmonella spp. To reduce the risk of bacterial growth, products are treated with a combination of low pH, addition of sugar, salt and preservatives, and a thermal process that can eliminate pathogens and extend shelf-life. In the case of yeasts and molds, chemical preservatives such as sorbates and propionates are used to inhibit their growth.
=== Insulinoma === Insulinoma is a rare tumor derived from the neoplasia of beta cells. Insulinomas are usually benign, but may be medically significant and even life-threatening due to recurrent and prolonged attacks of hypoglycemia.
By March 1940 the Oxford team had sufficient impure penicillin to commence testing whether it was toxic. Over the next two months, Florey and Jennings conducted a series of experiments on rats, mice, rabbits and cats in which penicillin was administered in various ways. Their results showed that penicillin was destroyed in the stomach, but that all forms of injection were effective, as indicated by assay of the blood. It was found that penicillin was largely and rapidly excreted unchanged in their urine. They found no evidence of toxicity in any of their animals. Had they tested against guinea pigs, research might have halted at this point, for penicillin is toxic to guinea pigs. At 11:00 am on Saturday 25 May 1940, Florey injected eight mice with a virulent strain of Streptococcus, and then injected four of them with the penicillin solution. These four were divided into two groups: two of them received 10 milligrams once, and the other two received 5 milligrams at regular intervals. By 3:30 am on Sunday all four of the untreated mice were dead. All of the treated ones were still alive, although one died two days later. Florey described the result to Jennings as "a miracle." Jennings and Florey repeated the experiment on Monday with ten mice; this time, all six of the treated mice survived, as did one of the four controls. On Tuesday, they repeated it with sixteen mice, administering different doses of penicillin. All six of the control mice died within 24 hours but the treated mice survived for several days, although they were all dead in nineteen days.
Sources: en.wikipedia.org
== Diagnosis == Zinc concentrations are typically quantified using instrumental methods such as atomic absorption, emission, or mass spectroscopies; X-ray fluorescence; electro-analytical techniques (e.g., stripping voltammetry); or neutron activation analysis. Inductively coupled plasma atomic emission spectroscopy (ICP-AES) is used for zinc determinations in blood and tissue samples (NIOSH Method 8005) and in urine (NIOSH Method 8310). Detection limits in blood and tissue are 1 μg/100 g and 0.2 μg/g, respectively, with recoveries of 100% (NIOSH 1994). Sample preparation involves acid digestion using concentrated acids. Detection of zinc in urine samples requires extraction of the metals with a polydithiocarbamate resin prior to digestion and analysis (NIOSH 1984). Detection limits in urine are 0.1 μg/sample.
The ability of birds to return to precise locations across vast distances has been known for some time; in an experiment conducted in the 1950s, a Manx shearwater released in Boston in the United States returned to its colony in Skomer, in Wales within 13 days, a distance of 5,150 km (3,200 mi). Birds navigate during migration using a variety of methods. For diurnal migrants, the sun is used to navigate by day, and a stellar compass is used at night. Birds that use the sun compensate for the changing position of the sun during the day by the use of an internal clock. Orientation with the stellar compass depends on the position of the constellations surrounding Polaris. These are backed up in some species by their ability to sense the Earth's geomagnetism through specialised photoreceptors.
=== Criminal prosecutions and convictions === In 2019, Schmitt launched the SAFE Kit Initiative to reduce the backlog of untested sexual assault kits in Missouri. As of October 2021, approximately two thousand kits had been examined under the initiative and thousands remained to be tested. In January 2020, Schmitt prosecuted a murder case in the City of St. Louis. The jury returned a quick verdict, finding Antonio Muldrew guilty of first-degree murder for shooting and killing Ethiopian refugee Abdulrauf Kadir at a convenience store in 2014. This was the first time a Missouri attorney general prosecuted a murder case in the City of St. Louis. On July 21, 2020, Schmitt filed amicus briefs that argued that "Missouri's statutes specifically authorize Missouri citizens to use firearms to deter assailants and protect themselves, their families, and homes from threatening or violent intruders" and requested dismissal of cases filed by prosecutor Kimberly Gardner against Patricia and Mark Thomas McCloskey for brandishing firearms at protesters who had trespassed on their property while marching in St. Louis in 2020. Schmitt expressed concern about "the chilling effect that this [case] might have with people exercising their Second Amendment rights." Schmitt opposed motions calling for the release of Lamar Johnson, who was convicted for murder on the basis of a single eyewitness's testimony, after a conviction integrity unit found "overwhelming evidence" of Johnson's innocence in 2019. Prior to hearings on his release, Schmitt unsuccessfully called for sanctions on St.
Sources: en.wikipedia.org
1993/2657) Private Legislation Procedure (Scotland) General Order 1993 (S.I. 1993/2660) European Communities (Designation) (No. 3) Order 1993 (S.I. 1993/2661) Birmingham City Council (Grand Union Canal Bridge) Scheme 1991 Confirmation Instrument 1993 (S.I. 1993/2662) European Convention on Extradition (Fiscal Offences) Order 1993 (S.I. 1993/2663) Admiralty Jurisdiction (Guernsey) Order 1993 (S.I. 1993/2664) Agriculture (Northern Ireland) Order 1993 (S.I. 1993/2665) Arms Control and Disarmament (Privileges and Immunities) Act 1988 (Guernsey) Order 1993 (S.I. 1993/2666) European Convention on Extradition (Hungary and Poland) (Amendment) Order 1993 (S.I. 1993/2667) Industrial Relations (Northern Ireland) Order 1993 (S.I. 1993/2668) Treaty on Open Skies (Privileges and Immunities) (Guernsey) Order 1993 (S.I. 1993/2669) Air Navigation (Fifth Amendment) Order 1993 (S.I. 1993/2670) Birmingham Heartlands Hospital National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/2680) Croydon Community National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/2681) Herefordshire Community Health National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/2682) Princess Royal Hospital National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/2683) Ravensbourne Priority Health National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/2684) St. Helier National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I.
== Early life and education == Minnich was born on January 24, 1910, in Zanesville, Ohio, and raised on her family's farm. She suffered severe burns at the age of four when her dress caught fire from a gas stove and she underwent close to thirty operations to correct the resultant disfigurement. Despite the surgeries, she was left with considerable scarring to her face, neck, and upper body that led some colleagues to discourage her from jobs requiring much human interaction. She had wanted to become a nurse, but was discouraged from this career path, so she decided to study to become a dietician. She received a Bachelor of Science in Home Economics from Ohio State University in 1937 and a master's degree in Nutrition from Iowa State College in 1938. In her senior year, Minnich worked part-time in the hematology laboratory of Carl V. Moore, with whom she would later work with extensively at Washington University. Minnich never received a doctorate degree, a decision which she regretted and which she attributed to dissuasion from Moore. She believed Moore's discouragement held back her salary and career advancement compared to men doing similar work.
== History == The existence of tRNA was first hypothesized by Francis Crick as the "adaptor hypothesis" based on the assumption that there must exist an adapter molecule capable of mediating the translation of the RNA alphabet into the protein alphabet. Paul C Zamecnik, Mahlon Hoagland, and Mary Louise Stephenson discovered tRNA in 1958. Significant research on structure was conducted in the early 1960s by Alex Rich and Donald Caspar, two researchers in Boston, the Jacques Fresco group in Princeton University and a United Kingdom group at King's College London. In 1965, Robert W. Holley of Cornell University reported the primary structure and suggested three secondary structures. tRNA was first crystallized in Madison, Wisconsin, by Robert M. Bock. The cloverleaf structure was ascertained by several other studies in the following years and was finally confirmed using X-ray crystallography studies in 1974. Two independent groups, Kim Sung-Hou working under Alexander Rich and a British group headed by Aaron Klug, published the same crystallography findings within a year.
This sequence can be easily accessed through the NCBI website and is used in many real-life applications. For example, the FBI has compiled a set of DNA marker sites used for identification, and these are called the Combined DNA Index System (CODIS) DNA database. Using this database enables statistical analysis to be used to determine the probability that a DNA sample will match. PCR is a very powerful and significant analytical tool to use for forensic DNA typing because researchers only need a very small amount of the target DNA to be used for analysis. For example, a single human hair with an attached hair follicle has enough DNA to conduct the analysis. Similarly, a few sperm, skin samples from under the fingernails, or a small amount of blood can provide enough DNA for conclusive analysis. Less discriminating forms of DNA fingerprinting can help in DNA paternity testing, where an individual is matched with their close relatives. DNA from unidentified human remains can be tested and compared with that from possible parents, siblings, or children. Similar testing can be used to confirm the biological parents of an adopted (or kidnapped) child. The actual biological father of a newborn can also be confirmed (or ruled out). The PCR AMGX/AMGY design has been shown to not only facilitate amplifying DNA sequences from a very minuscule amount of genome. However, it can also be used for real-time sex determination from forensic bone samples. This provides a powerful and effective way to determine gender in forensic cases and ancient specimens.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.